Written by The U.S. and China asthma and COPD drugs market is positioned for steady expansion, supported by the growing burden of respiratory diseases, improvements in diagnosis, increasing patient awareness, and continued innovation in drug development. Based on the supplied market data, the market was valued at US$13.0 billion in 2015 and was projected to reach US$18.7 billion by 2024, representing a 4.1% CAGR during 2016–2024. Growth is influenced by the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD), while patent expirations and subsequent price erosion can moderate revenue growth in the earlier years. At the same time, new therapies, combination treatments, and biologic drug candidates are creating opportunities for pharmaceutical companies to offset pricing pressure and address unmet treatment needs.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15857
Market Size and Growth
The market’s growth trajectory reflects the interaction of increasing disease prevalence and pharmaceutical innovation. Asthma and COPD continue to generate substantial demand for maintenance and symptom-control therapies, while advances in diagnostic approaches are helping identify patients who require long-term treatment. The supplied forecast indicates that new drug candidates emerging around 2020 and beyond could support a stronger growth path following the initial impact of patent expirations. Combination therapies are particularly important because they bring multiple mechanisms of action into a single treatment strategy and are widely used in respiratory disease management. Increasing investment in biologics and targeted therapies is also expected to create additional revenue opportunities across the market.
Market Segmentation
By drug class, the market includes bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Combination drugs represented the largest segment, accounting for approximately 54% of the market in 2015, according to the supplied data. Their widespread adoption is associated with treatment approaches promoted by organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA). Meanwhile, monoclonal antibodies represent an emerging area of interest, particularly as pharmaceutical companies introduce newer biologic candidates designed to address specific inflammatory pathways and patient populations.
Regional Analysis
The U.S. accounted for more than 81% of the combined U.S. and China market in 2016, reflecting higher drug prices, greater healthcare spending, strong consumer awareness, and continued investment in pharmaceutical research and development. The country also benefits from frequent product launches and substantial innovation in combination therapies and biologics. China, however, presents significant expansion potential. The supplied forecast estimated a 10% CAGR for China’s asthma and COPD drugs market between 2016 and 2024, supported by increasing asthma prevalence, air-pollution concerns, smoking-related COPD, and substantial unmet medical needs. Expanding healthcare access and pharmaceutical development further contribute to China’s market opportunity.
Competitive Landscape
The competitive environment includes major pharmaceutical companies with established respiratory portfolios and significant research capabilities. Companies identified in the supplied market overview include Boehringer Ingelheim, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche. Competition is shaped by product innovation, clinical development, combination therapies, biologics, pricing strategies, and efforts to expand treatment access. Patent expirations also create opportunities for generic competition while encouraging established companies to develop next-generation therapies and differentiated formulations.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453